The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04840069
Recruitment Status : Recruiting
First Posted : April 9, 2021
Last Update Posted : January 13, 2023
Barrow Neurological Foundation
Arizona Biomedical Research Commission (ABRC)
Blue Earth Diagnostics
Information provided by (Responsible Party):
St. Joseph's Hospital and Medical Center, Phoenix

Brief Summary:
The purpose of the this study is to see if the use of a PET scan with 18F-fluciclovine (PET or Fluciclovine PET) in addition to the normal radiation planning imaging procedures (MRI and CT scan) will help determine the areas where the radiation therapy is to be delivered. It is also a goal of the study to determine if subjects live longer when treatment plans for radiation therapy are designed using a Fluciclovine PET scan, as well as MRI and CT scans. We will also collect information on if and where the tumor returns. Information on the side effects from the two different treatment planning imaging methods will also be collected. 18F-Fluciclovine is an FDA-approved radioactive diagnostic agent that is injected into the patient and then taken up by cancer cells, which can then be visualized with a PET/CT scan. 18F-Fluciclovine is FDA approved for the detection of recurrent prostate cancer, but is still investigational for the purposes of this study.

Condition or disease Intervention/treatment Phase
Newly Diagnosed Glioblastoma Drug: Fluciclovine PET guided Radiotherapy Phase 2

Detailed Description:

The goal of this study is to see if the use of PET in planning radiotherapy can reduce these local failures.

Glioblastoma (GBM) is the most common primary malignant brain tumor. Newly diagnosed glioblastoma management includes maximum safe resection followed by radiotherapy with concurrent temozolomide, followed by maintenance temozolomide for 6 - 12 cycles. This postoperative chemoradiotherapy approach has resulted in a significant increase in median PFS (5.0 vs. 6.9 months) and OS (12.1 vs. 14.6 months) compared to radiotherapy alone (Stupp 2005). However, despite such multi-modality therapy, the median survival for GBM remains poor at approximately 15-16 months in contemporary series (Grossman, Ye et al. 2010, Gilbert, Wang et al. 2013 vs 2010).

Recently, a randomized trial of tumor-treating fields (TTF or Optune) plus temozolomide demonstrated the benefit of this treatment in newly diagnosed glioblastoma that led to FDA approval of the device (Stupp 2015, Stupp 2017). However despite these advances, most patients still have a poor prognosis with median survival of 16-21 months. Although adjuvant chemoradiotherapy has been shown to increase survival, a predominant pattern of failure remains local (Chan, Lee et al. 2002, Milano, Okunieff et al. 2010). Therefore, better therapeutic options are needed for this disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Clinical Trial of Radiotherapy Planning Using Conventional Imaging +/- Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma
Actual Study Start Date : June 7, 2021
Estimated Primary Completion Date : March 30, 2024
Estimated Study Completion Date : March 30, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: MRI-guided radiotherapy
Patients will undergo standard of care MRI-guided radiotherapy.
Experimental: MRI + Fluciclovine PET-guided radiotherapy
Patients will undergo MRI + Fluciclovine PET-guided radiotherapy
Drug: Fluciclovine PET guided Radiotherapy
PET+MRI Based There is no GTV_5400. The GTV_6000 will be defined as the surgical cavity inclusive of any remaining tumor enhancement and the hypermetabolic volume. CTV_5400 will include the GTV_6000 plus a margin of 1.0 cm which may be reduced around natural barriers to tumor growth such as the skull, ventricles, falx, etc. CTV_5400 must also include the entirety of the GTV_6000. There is no CTV_6000. PTV_5400 is the CTV_5400 plus a geometric 3 mm expansion in all dimensions; PTV_6000 is GTV_6000 plus a geometric 3 mm expansion in all dimensions. PTV may extend beyond bony margins and the skin surface. The PTV_5400 must contain the PTV_6000. In the setting of multi-focal disease, the primary target volumes will be defined as above, but for satellite lesions, the GTV_6000 will be defined as any tumor enhancement and hypermetabolic volume. There will be no CTV_6000. PTV_6000 will be defined as GTV_6000 plus a geometric 3 mm expansion in all dimensions.

Primary Outcome Measures :
  1. Patterns of Failure [ Time Frame: 36 months ]
    To assess whether incorporating fluciclovine PET into radiotherapy planning significantly changes the in-field and out-of-field radiographic progression rates, by comparison to traditional MRI-based radiotherapy

  2. Defining Tumor Volume [ Time Frame: 36 months ]
    2. To determine the effect fluciclovine PET has on definition of the tumor volume, as compared to traditional MRI-based radiotherapy.

Secondary Outcome Measures :
  1. Survival using MRI radiotherapy [ Time Frame: 36 months ]
    To quantify overall and progression free survival utilizing MRI cohort.

  2. Overall survival utilizing MRI+PET radiotherapy [ Time Frame: 36 months ]
    To quantify overall survival utilizing MRI+PET-based radiotherapy

  3. Progression free survival utilizing MRI+PET-based radiotherapy [ Time Frame: 36 months ]
    To quantify progression free survival utilizing MRI+PET-based

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological diagnosis of primary, newly diagnosed supratentorial, WHO grade IV glioma
  • Greater than 18 years of age
  • Karnofsky performance score greater than 70%
  • Recovered from surgery and on a stable or tapering dose of corticosteroids
  • Plan to undergo standard therapy with XRT 60Gy/30fx with TMZ followed by 6-12 cycles of maintenance TMZ within 6 weeks of surgery
  • If woman of child bearing potential, negative serum pregnancy test. Patients must agree to take adequate pregnancy preventions for the length of the study.
  • Life expectancy of at least 3 months
  • Written study specific consent

Exclusion Criteria:

  • Previous treatment of glioma of any grade with bevacizumab or other molecular targeted therapies less than 6 months before MRI (and PET) used for radiotherapy planning
  • Recurrent of multifocal malignant glioma
  • Any sites of distant disease (for example drop metastases or leptomeningeal spread)
  • Prior use of Gliadel wafers or any other intratumal or intracavity treatment
  • Prior radiotherapy to the cranium, head and neck or other sites resulting in overlapping fields
  • Molecular targeted therapies planned during radiotherapy
  • Simultaneous participation in other interventional trials which could interfere with this trial or participation in a clinical trial within the last thirty days before patient's enrollment in current study.
  • Inability to undergo an MRI or PET (Claustrophobia, non-MRI compatible pacemaker, known allergy to MRI contrast agent or fluciclovine tracer)
  • Any pregnant or lactating patient
  • Any prior malignancy within 3 years excluding carcinoma in-situ or early staged,localized basal or squamous cell skin cancers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04840069

Layout table for location contacts
Contact: Phase 0 Navigator 602-406-8605

Layout table for location information
United States, Arizona
St. Joseph's Hospital and Medical Center Recruiting
Phoenix, Arizona, United States, 85013
Contact: Phase 0 Navigator    602-406-8605   
Principal Investigator: Igor Barani, MD         
Sponsors and Collaborators
St. Joseph's Hospital and Medical Center, Phoenix
Barrow Neurological Foundation
Arizona Biomedical Research Commission (ABRC)
Blue Earth Diagnostics
Layout table for additonal information
Responsible Party: St. Joseph's Hospital and Medical Center, Phoenix Identifier: NCT04840069    
Other Study ID Numbers: 090-20-16
First Posted: April 9, 2021    Key Record Dates
Last Update Posted: January 13, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue